Viewing data from:

ARFORMOTEROL TARTRATE

ANDA

ARFORMOTEROL TARTRATE | A200293 | TEVA PHARMACEUTICALS USA

1 strength0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Arformoterol Tartrate (2023)

Total Spending

$4.4M

Total Claims

12,789

Beneficiaries

3,531

Avg Cost/Unit

$4.48

Spending Trend

$1.5M(2021)→$3.5M(2022)→$4.4M(2023)

YoY Change:-3.8%

5yr CAGR:-10.8%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain5 active DMFs

4 active API suppliers hold Drug Master Files for this ingredient.

CIPLA LTDARFORMOTEROL TARTRATE

DMF 229682009

MSN LABORATORIES PRIVATE LTDARFORMOTEROL TARTRATE [ROUTE CODE - "LT"]

DMF 280132014

ALIVUS LIFE SCIENCES LTDARFORMOTEROL TARTRATE

DMF 288682015

INKE SAARFORMOTEROL TARTRATE (FORM D)

DMF 329902018

INKE SAARFORMOTEROL TARTRATE (FORM A)

DMF 364352022

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (1)

#001 — EQ 0.015MG BASE/2ML

0 patents0 exclusivities▴

SOLUTION;INHALATION | Approved: Nov 9, 2021

No patent or exclusivity listings for this strength.